A Phase 2 interventional study of lenalidomide in Myelodysplastic Syndromes, sponsored by Celgene. Completed at 32 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-11-19.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing lenalidomide in Myelodysplastic Syndromes — none open to participants now, none under way, none of them phase 3. Lenalidomide · Myelodysplastic Syndromes.
Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, this one is the 5th largest by enrollment of the 43 interventional ones that give a count, is one of 2 that started in 2003, is one of 24 in phase 2, and was the 3rd registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 323 are open to participants now.
Browse Myelodysplastic Syndromes studies →None of the 44 studies testing lenalidomide in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 31 · Phase 3 3
First in 2002; this study’s year is marked. 2 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 148 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 32 across the 43 interventional studies. Of the 38 that completed or were terminated, 21 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb: 4 open now, 9 under way, 5 of them phase 3. Of 63 finished, 20 (32%) have results posted.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 15th largest by enrollment of the 46 interventional ones that give a count, is one of 3 that started in 2003, is one of 14 in phase 2, and was the 5th registered.
Bristol-Myers Squibb’s Myelodysplastic Syndromes studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 75 in Myelodysplastic Syndromes:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, single-arm, open-label study of oral lenalidomide monotherapy administered to red blood cell (RBC) transfusion-dependent subjects with low- or intermediate-1-risk Myelodysplastic Syndromes (MDS) associated with a del (5q31-33) cytogenetic abnormality. Screening procedures will take place within 28 days of the first day of lenalidomide treatment. Subjects will receive lenalidomide in 28-day cycles for up to 6 cycles, or until bone marrow disease progression or progression/relapse following erythroid hematologic improvement is documented. Study visits will occur every cycle (every 28 days) and laboratory monitoring to assess hematological parameters will occur every 14 days. Safety and efficacy assessments to be performed during the study are outlined in the Schedule of Study Assessments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: lenalidomide
10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
Also known as: CC-5013
Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence
Number of participants who achieved RBC-transfusion independence, which was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (eg, Days 1 to 56, Days 2 to 57, Days 3 to 58, etc), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin.
Time frame: Up to 2 years
Participants With Adverse Experiences
Counts of study participants who had adverse events (AEs) during the study. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator. The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.
Time frame: Up to 2 Years
Participants With a >= 50% Decrease From Baseline in Red Blood Cell (RBC) Transfusion Requirements Over Any Consecutive 56 Days During Study
A participant was categorized as having a transfusion reduction response if there was a ≥ 50% decrease from pretreatment transfusion requirements (before the start of the study mediation) compared to any consecutive 56 days during the study (i.e. post treatment).
Time frame: Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)
Time to Transfusion Independence
Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Time to transfusion independence was defined as the day of the first dose of study drug to the first day of the first 56-day RBC transfusion-free period.
Time frame: up to 2 years
Participants Who Relapsed or Maintained Their Transfusion Independence After Achieving Transfusion Independence During the Study
Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Participants who relapsed required a transfusion after the period of transfusion independence. Participants who maintained transfusion independence did not require a transfusion during the remainder of the study.
Time frame: up to 2 years
Kaplan Meier Estimate for Duration of Transfusion Independence Response
Duration of response is measured from the first of the consecutive 56 days during which the participant was free of RBC transfusions to the date of the first RBC transfusion after this period. Duration of response was censored at the date of last visit for participants who maintained transfusion independence.
Time frame: up to 2 years
Change in Hemoglobin Concentration From Baseline to Maximum Value During Response Period for Responders
The change from baseline in hemoglobin for participants who became RBC-transfusion independent. The maximum hemoglobin value obtained during the response period is used in the calculation of change from baseline.
Time frame: Baseline (Day -54 to Day 0), During study (Day 1 up to 2 years)
Participant Counts of Cytogenetic Response
Participants deemed evaluable by the central cytogenetic review had their cytogenetic response categorized as major or minor. A major cytogenetic response was defined as ≥ 20 metaphases recorded at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with no abnormal metaphases observed. A minor cytogenetic response was defined as ≥ 20 metaphases analyzed at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with a ≥ 50% reduction in the proportion of hematopoietic cells with cytogenetic abnormalities compared with baseline.
Time frame: up to 2 years
Participant Counts of Platelet Response
Major platelet response: participants with a minimum pretreatment platelet of \<100,000/mm\^3 in all values within 56 days of start of treatment, an absolute increase of ≥30,000/mm\^3 sustained for ≥56 consecutive days. In platelet transfusion-dependent participants, a major response was stabilization of platelet counts and platelet transfusion independence. Minor platelet response: participants with a minimum pretreatment platelet of \<100,000/mm\^3, a ≥ 50% increase in platelet count with a net increase \>10,000/mm\^3 for a consecutive 56-day period in the absence of platelet transfusions.
Time frame: up to 2 years
Participant Counts of Absolute Neutrophil Count (ANC) Response
Major neutrophil response: participants with a minimum pretreatment ANC concentration of \< 1500/mm\^3 in all values obtained within 56 days of start of treatment, a ≥ 100% increase or an absolute increase of ≥ 500/mm\^3, whichever was greater (at least to be ≥ 500/mm\^3), sustained for 56 consecutive days. Minor neutrophil response: participants with a minimum pretreatment ANC concentration of \< 1500/mm\^3, an increase in ANC concentration of ≥ 100% sustained for 56 consecutive days.
Time frame: up to 2 years
Participants With Complete or Partial Bone Marrow Improvement
Bone marrow aspirates were assessed by a central reviewer. A complete bone marrow improvement required a baseline French-American-British (FAB) classification (see Baseline Characteristics) of refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB) or chronic myelomonocytic leukemia (CMML) and a during study assessment of no MDS. A partial bone marrow improvement reflected an improved FAB classification compared to baseline (e.g. RARS to RA) but evidence of MDS continued to exist.
Time frame: up to 2 years
Participants With Bone Marrow Progression
Bone marrow aspirate was assessed by a central reviewer. Progression is represented in two categories according to changes from baseline in French-American-British (FAB) classification (see Baseline Characteristics): * Baseline classification of refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) to a during treatment (plus 30 days) classification of refractory anemia with excess blasts (RAEB). * Any baseline FAB classification to a during treatment (plus 30 days) classification of acute myeloid leukemia (AML).
Time frame: up to 2 years
| Milestone | Lenalidomide |
|---|---|
| Started | 148 |
| Modified intent to treat population | 94 |
| Completed | 24 |
| Not completed | 124 |
| Withdrew: Adverse event | 37 |
| Withdrew: Lack of efficacy | 52 |
| Withdrew: Withdrawal by subject | 8 |
| Withdrew: Lost to follow-up | 1 |
| Withdrew: Death | 11 |
| Withdrew: Study closed by sponsor | 2 |
| Withdrew: Disease progression | 7 |
| Withdrew: Investigator decision | 2 |
| Withdrew: Non-compliance | 2 |
| Withdrew: Loss of response | 1 |
| Withdrew: Secondary malign disease | 1 |
Number of participants who achieved RBC-transfusion independence, which was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (eg, Days 1 to 56, Days 2 to 57, Days 3 to 58, etc), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin.
| participants | Lenalidomide |
|---|---|
| Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence | 59 |
Counts of study participants who had adverse events (AEs) during the study. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator. The National Cancer Institute (NCI)'s Common Toxicity Criteria for AEs (NCI CTC) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.
| participants | Lenalidomide |
|---|---|
| At least one AE | 148 |
| At least one AE related to study drug | 143 |
| At least one NCI CTC grade 3-4 AE | 140 |
| At least one NCI CTC grade 3-4 AE related to drug | 131 |
| At least one serious AE | 89 |
| At least one serious AE related to study drug | 40 |
| AE leading to dose reduction or interruption | 131 |
| AE leading to discontinuation of study drug | 47 |
A participant was categorized as having a transfusion reduction response if there was a ≥ 50% decrease from pretreatment transfusion requirements (before the start of the study mediation) compared to any consecutive 56 days during the study (i.e. post treatment).
| participant | Lenalidomide |
|---|---|
| Participants With a >= 50% Decrease From Baseline in Red Blood Cell (RBC) Transfusion Requirements Over Any Consecutive 56 Days During Study | 70 |
Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Time to transfusion independence was defined as the day of the first dose of study drug to the first day of the first 56-day RBC transfusion-free period.
| weeks | Lenalidomide |
|---|---|
| Time to Transfusion Independence | 6.2 ± 6.89 |
Transfusion independence was defined as the absence of an intravenous infusion of any RBC transfusion during any consecutive "rolling" 56 days during the treatment period (e.g., Days 1 to 56, Days 2 to 57, Days 3 to 58, etc.), and accompanied by at least a 1 g/dL increase from screening/baseline in hemoglobin. Participants who relapsed required a transfusion after the period of transfusion independence. Participants who maintained transfusion independence did not require a transfusion during the remainder of the study.
| participants | Lenalidomide |
|---|---|
| Relapsed (had a transfusion after response) | 35 |
| Maintained transfusion independence | 24 |
Duration of response is measured from the first of the consecutive 56 days during which the participant was free of RBC transfusions to the date of the first RBC transfusion after this period. Duration of response was censored at the date of last visit for participants who maintained transfusion independence.
| weeks | Lenalidomide |
|---|---|
| Kaplan Meier Estimate for Duration of Transfusion Independence Response | 97.0 (52.9 to 191.9) |
The change from baseline in hemoglobin for participants who became RBC-transfusion independent. The maximum hemoglobin value obtained during the response period is used in the calculation of change from baseline.
| g/dL | Lenalidomide |
|---|---|
| Change in Hemoglobin Concentration From Baseline to Maximum Value During Response Period for Responders | 6.1 ± 1.92 |
Participants deemed evaluable by the central cytogenetic review had their cytogenetic response categorized as major or minor. A major cytogenetic response was defined as ≥ 20 metaphases recorded at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with no abnormal metaphases observed. A minor cytogenetic response was defined as ≥ 20 metaphases analyzed at baseline, and at least 1 post baseline evaluation with ≥ 20 metaphases analyzed with a ≥ 50% reduction in the proportion of hematopoietic cells with cytogenetic abnormalities compared with baseline.
| participants | Lenalidomide |
|---|---|
| Major | 18 |
| Minor | 20 |
| None | 14 |
Major platelet response: participants with a minimum pretreatment platelet of \<100,000/mm\^3 in all values within 56 days of start of treatment, an absolute increase of ≥30,000/mm\^3 sustained for ≥56 consecutive days. In platelet transfusion-dependent participants, a major response was stabilization of platelet counts and platelet transfusion independence. Minor platelet response: participants with a minimum pretreatment platelet of \<100,000/mm\^3, a ≥ 50% increase in platelet count with a net increase \>10,000/mm\^3 for a consecutive 56-day period in the absence of platelet transfusions.
| participants | Lenalidomide |
|---|---|
| Major | 2 |
| Minor | 0 |
| None | 13 |
Major neutrophil response: participants with a minimum pretreatment ANC concentration of \< 1500/mm\^3 in all values obtained within 56 days of start of treatment, a ≥ 100% increase or an absolute increase of ≥ 500/mm\^3, whichever was greater (at least to be ≥ 500/mm\^3), sustained for 56 consecutive days. Minor neutrophil response: participants with a minimum pretreatment ANC concentration of \< 1500/mm\^3, an increase in ANC concentration of ≥ 100% sustained for 56 consecutive days.
| participant | Lenalidomide |
|---|---|
| Major | 9 |
| Minor | 0 |
| None | 18 |
Bone marrow aspirates were assessed by a central reviewer. A complete bone marrow improvement required a baseline French-American-British (FAB) classification (see Baseline Characteristics) of refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB) or chronic myelomonocytic leukemia (CMML) and a during study assessment of no MDS. A partial bone marrow improvement reflected an improved FAB classification compared to baseline (e.g. RARS to RA) but evidence of MDS continued to exist.
| participants | Lenalidomide |
|---|---|
| Complete bone marrow improvement | 22 |
| Partial bone marrow improvement | 15 |
Bone marrow aspirate was assessed by a central reviewer. Progression is represented in two categories according to changes from baseline in French-American-British (FAB) classification (see Baseline Characteristics): * Baseline classification of refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) to a during treatment (plus 30 days) classification of refractory anemia with excess blasts (RAEB). * Any baseline FAB classification to a during treatment (plus 30 days) classification of acute myeloid leukemia (AML).
| participants | Lenalidomide |
|---|---|
| RA/RARS to RAEB | 11 |
| RA/RARS/RAEB/CMML to AML | 6 |
Collected over Up to 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lenalidomide | — | 89/148 (60.1%) | 148/148 (100%) |
| Event | Lenalidomide |
|---|---|
| Pneumonia Not Otherwise Specified (NOS)Infections and infestations | 15/148 |
| NeutropeniaBlood and lymphatic system disorders | 10/148 |
| Anaemia NOSBlood and lymphatic system disorders | 8/148 |
| DehydrationMetabolism and nutrition disorders | 8/148 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 8/148 |
| Acute Leukaemia NOSNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 7/148 |
| Cardiac Failure CongestiveCardiac disorders | 6/148 |
| Sepsis NOSInfections and infestations | 6/148 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/148 |
| Deep Vein ThrombosisVascular disorders | 5/148 |
| Event | Lenalidomide |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 93/148 |
| NeutropeniaBlood and lymphatic system disorders | 91/148 |
| Diarrhoea Not Otherwise Specified (NOS)Gastrointestinal disorders | 87/148 |
| PruritusSkin and subcutaneous tissue disorders | 66/148 |
| FatigueGeneral disorders | 62/148 |
| Rash NOSSkin and subcutaneous tissue disorders | 54/148 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 46/148 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 44/148 |
| NauseaGastrointestinal disorders | 41/148 |
| Oedema PeripheralGeneral disorders | 40/148 |
| Age, Continuous(years) | Lenalidomide |
|---|---|
| Mean | 70.0 ± 10.50 |
| Age, Customized(participants) | Lenalidomide |
|---|---|
| <= 65 years | 48 |
| >65 years | 100 |
| Sex: Female, Male(Participants) | Lenalidomide |
|---|---|
| Female | 97 |
| Male | 51 |
| Race/Ethnicity, Customized(participants) | Lenalidomide |
|---|---|
| White | 143 |
| Hispanic | 3 |
| Asian/Pacific Islander | 2 |
| Region of Enrollment(participants) | Lenalidomide |
|---|---|
| United States | 112 |
| Germany | 36 |
| Duration of Myelodysplastic Syndrome (MDS)(years) | Lenalidomide |
|---|---|
| Mean | 3.4 ± 3.29 |
| Participants with 5q(-) (31-33) Chromosomal Abnormality(participants) | Lenalidomide |
|---|---|
| Number | 148 |
| International Prognostic Scoring System (IPSS) Score(participants) | Lenalidomide |
|---|---|
| Low (0) | 49 |
| Intermediate-1 (0.5 to 1.0) | 69 |
| Intermediate-2 (1.5 to 2.0) | 7 |
| High (>=2.5) | 2 |
| Missing (unable to assign) | 21 |
3 further baseline measures are reported on the registry.
Ran from Jun 2003 to primary completion in Aug 2008, 62 months.
Results were first posted in Jun 2010, 1 year 10 months after primary completion.
Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 62 months is above that.
Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide